| Literature DB >> 36046740 |
Jiaxing Tan1,2, Ming Chen2, Yutong Wang2, Yi Tang1,2, Wei Qin1,2.
Abstract
The clinical value of the relationship between gastrointestinal microbiome imbalance and its corresponding interventions with kidney disease is emerging. This study describes the hotspots and evolution of gastrointestinal microbiome and kidney disease research over the past three decades by scientific collaboration networks and finally predicts future trends in the field through bibliometric analysis and visualization studies. CiteSpace was used to explore the original articles from January 1990 to August 2021 to visualize the knowledge network of journals, countries, institutions, authors, references, and keywords in this field. Publications were extracted from Web of Science Core Collection database using the terms "gastrointestinal microbiome" and "kidney disease" (and their synonyms in MeSH). A total of 2145 publications with 93880 references in 102 journals were included in the analyses. The number of studies combining gastrointestinal microbiomes with kidney diseases has increased significantly over the past two decades. The United States is the leading country in the number of documents, and the leading institution is the Cleveland Clinic. The most landmark articles in the field are on chronic renal failure, L-Carnitin, and cardiovascular disease. The pathogenesis of uremia toxin is an emerging trend in gastrointestinal microbiomes and kidney diseases. In addition, probiotic or synbiotic supplements have strong clinical value in adjusting abnormal intestinal symbiotic environments. This study demonstrates a growing understanding of the interaction between gut microbiota and kidney disease over time. Using microbial supplements to improve the living conditions of kidney disease patients is a promising and hot research focus. Based on publications extracted from the database, this study may provide clinicians and researchers with valuable information to identify potential collaborators and partner institutions and better predict their dynamic progression.Entities:
Keywords: bibliometric; gastrointestinal microbiome; kidney disease; probiotics; research focus
Mesh:
Year: 2022 PMID: 36046740 PMCID: PMC9420905 DOI: 10.3389/fcimb.2022.946138
Source DB: PubMed Journal: Front Cell Infect Microbiol ISSN: 2235-2988 Impact factor: 6.073
Figure 1Workflow diagram of the publications search, screening, and analysis.
Figure 2Co-institution knowledge map in the field of gastrointestinal microbiome and kidney disease during 1990-2021. (A) Nodes show in the form of annual rings that the annual ring width represents how many papers the institution publishes in a given year. The more papers are published, the wider the ring is in that year. And the brighter the node is, the newer the publication. (B) Total distribution comparison of the top ten most published countries and centralities in the field of gastrointestinal microbiomes and kidney diseases. (C) Proportion of the top ten most published institutions.
Figure 3Co-country analysis in the field of gastrointestinal microbiomes and kidney diseases during 1990-2021. (A) Nodes show in the form of annual rings that the annual ring width represents how many papers the country publishes in a given year and the color. Nodes marked with purple circles represent convincible betweenness centrality, which stands for the importance of a certain object, and the warmer color the node is, the newer the publish is. The more papers are published, the wider the ring is in that year. (B) Total distribution comparison of the top ten most published countries and centralities in the field of gastrointestinal microbiomes and kidney diseases. (C) Proportion of the top ten most published countries. (D) Annual publications of the top three productive countries.
Top 10 most productive authors in the field of gastrointestinal microbiomes and kidney diseases.
| Rank | Author | Count | Year | Representative article in this field |
|---|---|---|---|---|
| 1 | Denise Mafra | 32 | 2015 | Probiotics and chronic kidney disease |
| 2 | Nosratola D Vaziri | 30 | 2012 | Chronic kidney disease alters intestinal microbial flora |
| 3 | Denis Fouque | 23 | 2013 | Probiotics and chronic kidney disease |
| 4 | Youlin Tain | 19 | 2018 | Maternal Administration of Probiotic or Prebiotic Prevents Male Adult Rat Offspring against Developmental Programming of Hypertension Induced by High Fructose Consumption in Pregnancy and Lactation |
| 5 | CHIENNING HSU | 18 | 2018 | Maternal Administration of Probiotic or Prebiotic Prevents Male Adult Rat Offspring against Developmental Programming of Hypertension Induced by High Fructose Consumption in Pregnancy and Lactation |
| 6 | MarkusmHeimesaat | 16 | 2012 | Intestinal Microbiota Shifts towards Elevated Commensal Escherichia coli Loads Abrogate Colonization Resistance against Campylobacter jejuni in Mice |
| 7 | Stefan Bereswill | 15 | 2012 | Intestinal Microbiota Shifts towards Elevated Commensal Escherichia coli Loads Abrogate Colonization Resistance against Campylobacter jejuni in Mice |
| 8 | Loreto Gesualdo | 15 | 2014 | Microbiota and Metabolome Associated with Immunoglobulin A Nephropathy (IgAN) |
| 9 | W.H.Wilson Tang | 14 | 2015 | Gut Microbiota-Dependent Trimethylamine N-Oxide (TMAO) Pathway Contributes to Both Development of Renal Insufficiency and Mortality Risk in Chronic Kidney Disease |
| 10 | Jennifer L Pluznick | 12 | 2013 | Olfactory receptor responding to gut microbiota-derived signals plays a role in renin secretion and blood pressure regulation |
Top 10 most productive journals in the field of gastrointestinal microbiomes and kidney diseases.
| Journals | Impact Factors (2021) | Number of publishedpapers |
|---|---|---|
| PLoS One | 3.24 | 1195 |
| Nature | 49.962 | 1032 |
| Kidney International | 10.612 | 956 |
| Journal Of The American Society Of Nephrology | 10.121 | 857 |
| Proceedings of the National Academy of Sciences of | 11.205 | 847 |
| Science | 47.728 | 743 |
| Gut | 23.059 | 721 |
| New England Journal Of Medicine | 91.245 | 713 |
| Nephrology Dialysis Transplantation | 5.992 | 712 |
| Scientific Reports-UK | 4.379 | 663 |
Burst detection of Co-keyword analysis [Prone: MST g=10].
| Keyword | Strength | Begin | End | 1990-2021 |
|---|---|---|---|---|
| chronic renal failure | 10.05 |
| 2017 |
|
| hemodialysis patient | 7.96 |
| 2017 |
|
| protein coupled receptor | 7.03 |
| 2016 |
|
| pathogenesis | 6.07 |
| 2016 |
|
| inflammatory bowel disease | 5.63 |
| 2018 |
|
| L-Carnitin | 10.18 |
| 2018 |
|
| bound uremic toxin | 7.21 |
| 2018 | |
| atherosclerosis | 5.8 |
| 2018 |
|
| cardiovascular disease | 10.39 |
| 2018 |
|
| therapy | 5.15 |
| 2019 |
|
| butyrate | 5.32 |
| 2021 |
|
The whole length of the green bar represents the research topic in a time span of 31 years according to the CiteSpace setting, and the red bar represents the lasting time of the hotspot and corresponding timespan.
Figure 4Co-citation knowledge map in the field of gastrointestinal microbiomes and kidney diseases during 1990-2021. Each node represents a research cluster, the size of the node represents the frequency of their occurrence, the line between nodes represents the degree of relevance, the thickness of lines indicates the strength of cooperation. The color of the lines and nodes corresponds to the publication time and the warmer color the color is, the newer the publish is.
The largest 12 clusters of gastrointestinal microbiomes and kidney diseases document co-citation, identified by keyword.
| Cluster ID | Size | Silhouette | Year | Label (LSI) | Label (LLR) | Label (MI) |
|---|---|---|---|---|---|---|
| 0 | 183 | 0.783 | 2016 | chronic kidney disease | chronic kidney disease | infrequent dialysis |
| 1 | 149 | 0.833 | 2012 | chronic kidney disease | uremia | minerals |
| 2 | 101 | 0.967 | 2016 | trimethylamine n-oxide | Trimetlylamine oxide | mortality prediction |
| 3 | 89 | 0.809 | 2014 | gut microbiota | hypertension | sensory receptor |
| 4 | 37 | 1 | 2013 | kidney stones | oxalate | tea |
| 5 | 31 | 0.964 | 2014 | renal cell carcinoma | immunotherapy | ascites |
| 7 | 26 | 0.976 | 2012 | chronic kidney disease | type 2 diabetes | antimicrobial |
| 12 | 14 | 1 | 2006 | compound list | metabonomics | chronic kidney disease |
| 16 | 12 | 0.993 | 2007 | farnesoid x receptor | G protein-coupled bile acid receptor 1 | chronic kidney disease |
| 26 | 9 | 0.996 | 2016 | uremic toxins | uric acid | chronic kidney disease |
| 45 | 6 | 0.995 | 2008 | bacterial translocation | microbiome dysbiosis | chronic kidney disease |
| 48 | 5 | 1 | 2011 | … | minerals | chronic kidney disease |
References with the strongest 25 citation bursts in the field of gastrointestinal microbiomes and kidney diseases.
| References | Year | Strength | Begin | End | 1990 - 2021 |
|---|---|---|---|---|---|
| Wang ZN, 2011, NATURE, V472, P57, DOI 10.1038/nature09922, DOI | 2011 | 21.31 | 2012 | 2016 |
|
| Aronov PA, 2011, J AM SOC NEPHROL, V22, P1769, DOI 10.1681/ASN.2010121220, DOI | 2011 | 19.78 | 2012 | 2016 |
|
| Ranganathan N, 2010, ADV THER, V27, P634 | 2010 | 13.05 | 2012 | 2015 |
|
| Meijers BKI, 2010, NEPHROL DIAL TRANSPL, V25, P219, DOI 10.1093/ndt/gfp414, DOI | 2010 | 11.86 | 2012 | 2015 | |
| Vaziri ND, 2013, KIDNEY INT, V83, P308, DOI 10.1038/ki.2012.345, DOI | 2013 | 37.19 | 2013 | 2018 |
|
| Anders HJ, 2013, KIDNEY INT, V83, P1010, DOI 10.1038/ki.2012.440, DOI | 2013 | 16.61 | 2013 | 2018 |
|
| Vaziri ND, 2012, NEPHROL DIAL TRANSPL, V27, P2686, DOI 10.1093/ndt/gfr624, DOI | 2012 | 14.58 | 2013 | 2017 |
|
| Vaziri ND, 2012, CURR OPIN NEPHROL HY, V21, P587, DOI 10.1097/MNH.0b013e328358c8d5, DOI | 2012 | 12.98 | 2013 | 2016 |
|
| Nakabayashi I, 2011, NEPHROL DIAL TRANSPL, V26, P1094, DOI 10.1093/ndt/gfq624, DOI | 2011 | 12.34 | 2013 | 2016 |
|
| Vaziri ND, 2012, AM J NEPHROL, V36, P438, DOI 10.1159/000343886, DOI | 2012 | 10.45 | 2013 | 2017 |
|
| Koeth RA, 2013, NAT MED, V19, P576, DOI 10.1038/nm.3145, DOI | 2013 | 22.91 | 2014 | 2018 |
|
| Pluznick JL, 2013, P NATL ACAD SCI USA, V110, P4410, DOI 10.1073/pnas.1215927110, DOI | 2013 | 13.94 | 2014 | 2018 |
|
| Vaziri ND, 2013, AM J NEPHROL, V37, P1, DOI 10.1159/000345969, DOI | 2013 | 13.43 | 2014 | 2018 |
|
| Qin JJ, 2012, NATURE, V490, P55, DOI 10.1038/nature11450, DOI | 2012 | 12.87 | 2014 | 2017 |
|
| Wu IW, 2011, NEPHROL DIAL TRANSPL, V26, P938, DOI 10.1093/ndt/gfq580, DOI | 2011 | 12.73 | 2014 | 2016 |
|
| Wang FQ, 2012, NEPHROLOGY, V17, P733, DOI 10.1111/j.1440-1797.2012.01647.x, DOI | 2012 | 12.48 | 2014 | 2017 |
|
| Tremaroli V, 2012, NATURE, V489, P242, DOI 10.1038/nature11552, DOI | 2012 | 9.74 | 2014 | 2017 |
|
| Tang WHW, 2013, NEW ENGL J MED, V368, P1575, DOI 10.1056/NEJMoa1109400, DOI | 2013 | 20.35 | 2015 | 2018 |
|
| Wong J, 2014, AM J NEPHROL, V39, P230, DOI 10.1159/000360010, DOI | 2014 | 15.41 | 2015 | 2019 |
|
| Ramezani A, 2014, J AM SOC NEPHROL, V25, P657, DOI 10.1681/ASN.2013080905, DOI | 2014 | 12.95 | 2015 | 2019 |
|
| Vaziri ND, 2014, PLOS ONE, V9, P0, DOI 10.1371/journal.pone.0114881, DOI | 2014 | 9.68 | 2016 | 2019 |
|
| Sirich TL, 2014, CLIN J AM SOC NEPHRO, V9, P1603, DOI 10.2215/CJN.00490114, DOI | 2014 | 9.68 | 2016 | 2019 |
|
| Li J, 2017, MICROBIOME, V5, P0, DOI 10.1186/s40168-016-0222-x, DOI | 2017 | 10.46 | 2019 | 2021 |
|
| Lau WL, 2018, CLIN SCI, V132, P509, DOI 10.1042/CS20171107, DOI | 2018 | 9.51 | 2019 | 2021 |
|
| Wilck N, 2017, NATURE, V551, P585, DOI 10.1038/nature24628, DOI | 2017 | 9.28 | 2019 | 2021 |
|
The whole length of the green bar represents the research topic in a time span of 31 years according to the CiteSpace setting, and the red bar represents the lasting time of the hotspot and corresponding timespan.
References with the strongest citation frequency in gastrointestinal microbiomes and kidney diseases. (TMAO: Trimetlylamine oxide).
| Frequency | Burst | Degree | Centrality | Sigma | Author | Year | Title | Source | Cluster |
|---|---|---|---|---|---|---|---|---|---|
| 159 | 28 | 0.01 | 1 | Tang WHW | 2015 |
| Circulation Research | #2 TMAO | |
| 155 | 37.19 | 39 | 0.01 | 1.41 | Vaziri ND | 2013 |
| Kidney International | #1 uremia |
| 133 | 12.95 | 15 | 0.01 | 1.07 | Ramezani A | 2014 |
| Journal of The American Society of Nephrology | #1 uremia |
| 130 | 15.41 | 45 | 0.02 | 1.39 | Wong J | 2014 |
| American Journal of Nephrology | #1 uremia |
| 102 | 50 | 0.03 | 1 | Rossi M | 2016 |
| Clinical Journal of the American Society of Nephrology | #1 uremia |